Literature DB >> 16935336

Clinical course of bimatoprost-induced periocular skin changes in Caucasians.

Manali Doshi1, Deepak P Edward, Smajo Osmanovic.   

Abstract

PURPOSE: To describe the demographic and clinical characteristics of bimatoprost-induced periocular skin hyperpigmentation in Caucasians.
DESIGN: Retrospective noncomparative case series. PARTICIPANTS: Thirty-seven Caucasian patients (29 female, 8 male) with a diagnosis of primary open-angle glaucoma (n = 28) or ocular hypertension (n = 9) in whom cosmetically noticeable periocular skin pigmentation developed with bimatoprost therapy.
METHODS: An unbiased examiner performed a retrospective chart analysis of patients in whom periocular skin hyperpigmentation developed after starting bimatoprost therapy. Data collected included patient demographics, diagnosis, medication history, dates of starting and stopping bimatoprost treatment, and subjective assessment of the periocular hyperpigmentation at initial detection and follow-up visits. MAIN OUTCOME MEASURES: Periocular hyperpigmentation was graded using an arbitrary scale from 0 to 3. The number of days to the onset of hyperpigmentation and to pigment resolution was determined and their associations to demographic and other clinical parameters were analyzed.
RESULTS: Patients had variable grades of periocular hyperpigmentation at presentation (mean, 1.27+/-0.50; range, 1-2.5). Bimatoprost-induced periocular hyperpigmentation appeared most frequently between 3 and 6 months after initiation of bimatoprost therapy (277+/-138 days). Resolution of skin hyperpigmentation was noted most frequently between 3 and 12 months (205+/-97 days); however, there was a wide range of 61 to 472 days. Thirty-three of the 37 patients had complete resolution of the periocular hyperpigmentation.
CONCLUSIONS: Bimatoprost use is associated with periocular skin hyperpigmentation in Caucasians with variable time of onset. The periocular hyperpigmentation appears gradually, but in this series was completely reversible on discontinuation of bimatoprost.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16935336     DOI: 10.1016/j.ophtha.2006.05.041

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Periorbital Hyperpigmentation: A Comprehensive Review.

Authors:  Rashmi Sarkar; Rashmi Ranjan; Shilpa Garg; Vijay K Garg; Sidharth Sonthalia; Shivani Bansal
Journal:  J Clin Aesthet Dermatol       Date:  2016-01

2.  Bimatoprost in the treatment of eyelash hypotrichosis.

Authors:  Simon K Law
Journal:  Clin Ophthalmol       Date:  2010-04-26

3.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

4.  Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases.

Authors:  Takaiko Yoshino; Takeo Fukuchi; Tetsuya Togano; Masaaki Seki; Hiroko Ikegaki; Haruki Abe
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

Review 5.  Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution.

Authors:  Daniel Lee; Anand V Mantravadi; Jonathan S Myers
Journal:  Clin Ophthalmol       Date:  2017-07-10

6.  Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma.

Authors:  Saki Fukaya; Masahiro Kamata; Tomoko Kasanuki; Makoto Yokobori; Shintaro Takeoka; Kotaro Hayashi; Takamitsu Tanaka; Atsuko Fukuyasu; Takeko Ishikawa; Takamitsu Ohnishi; Satoshi Iimuro; Yayoi Tada; Shinichi Watanabe
Journal:  J Dermatol       Date:  2018-08-29       Impact factor: 4.005

7.  Periorbital muscle atrophy associated with topical bimatoprost therapy.

Authors:  Priscilla Xinhui Wang; Victor Teck Chang Koh; Jin Fong Cheng
Journal:  Clin Ophthalmol       Date:  2014-01-29

8.  A Comparative Study of Two Modalities, 4% Hydroquinone Versus 30% Salicylic Acid in Periorbital Hyperpigmentation and Assessment of Quality of Life Before and After Treatment.

Authors:  Rashmi Ranjan; Rashmi Sarkar; Vijay Kumar Garg; Tanvi Gupta
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.